| Wang, Hua |
NCT06476210: The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB) |
|
|
| Recruiting | 4 | 45 | RoW | BDL regimen | Beijing Chest Hospital, Public Health Clinical Medical Center of Chengdu, Wuhan Institute for Tuberculosis Control, Changsha Central Hospital, Anhui Chest Hospital, Hunan Chest Hospital, Shandong Public Health Clinical Center | Pulmonary Tuberculosis | 06/25 | 06/26 | | |
PROSPECT, NCT05306223: A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China |
|
|
| Recruiting | 4 | 212 | RoW | Bedaquiline, SIRTURO, Levofloxacin, Linezolid, Cycloserine, Clofazimine, Pyrazinamide, Protionamide | Beijing Chest Hospital | Tuberculosis, Multidrug-Resistant | 08/25 | 08/25 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
INSPIRE-BDLL, NCT06649721: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort |
|
|
| Not yet recruiting | 3 | 120 | RoW | bedaquiline, BDQ, B, delamanid, DLM, D, linezolid, LZD, L, Levofloxacin, LFX, Clofazimine, CFZ, C | Huashan Hospital, Beijing Chest Hospital | Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis | 06/27 | 06/27 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort |
|
|
| Recruiting | 3 | 186 | RoW | Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB | Beijing Chest Hospital, National Medical Center for Infectious Diseases | Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | 10/26 | 12/26 | | |
| Recruiting | 2 | 90 | RoW | Pegaspargase combined with concurrent radiotherapy. | Sun Yat-sen University | Extranodal NK/T-cell Lymphoma | 03/26 | 03/26 | | |
NCT04254640: Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML |
|
|
| Not yet recruiting | 2 | 34 | RoW | Cladribine Injection, 2-chlorodeoxyadenosine, Aclarubicin, aclarubicin hydrochloride, G-CSF, Granulocyte Colony-Stimulating Factor, cytarabine, cytarabine hydrochloride | Sun Yat-sen University | Acute Myeloid Leukemia, Elderly Patients, Newly Diagnosed | 06/23 | 12/23 | | |
NCT04892498: Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) |
|
|
| Recruiting | 2 | 66 | RoW | Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF, IL-2 | Second Affiliated Hospital of Soochow University | Advanced Refractory Solid Tumors | 08/23 | 08/24 | | |
NCT02705508: PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma |
|
|
| Recruiting | 2 | 35 | RoW | Gemcitabine, Gemzar, etoposide, Etoposide phosphate, Pegaspargase, Oncaspar, involved-field radiotherapy, IFRT | Sun Yat-sen University, China Food and Drug Administration | Treatment Refusal | 12/23 | 12/23 | | |
SPENT, NCT04676789: Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL |
|
|
| Not yet recruiting | 2 | 30 | RoW | Pegaspargase, P-ASP, Anti-PD-1 monoclonal antibody, sintilimab, Definitive intensity-modulated radiotherapy (IMRT), IMRT | Sun Yat-sen University | Extranodal NK/T-cell Lymphoma, Nasal Type | 09/24 | 12/24 | | |
NCT05564897: Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer |
|
|
| Recruiting | 2 | 25 | RoW | H101, Camrelizumab | Zhejiang Cancer Hospital | Bladder Cancer | 09/24 | 12/24 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
NCT02396043: Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma |
|
|
| Recruiting | 2 | 50 | RoW | induction phase1, Vincristine,Pirarubicin,Prednisone,Pegaspargase, induction phase2, Cyclophosphamide,Cytarabine,Mercaptopurine, protocol M, Methotrexate,Mercaptopurine, maintenance therapy, 6-mercaptopurine,Methotrexate, reinduction phase1, reinduction phase2, Intrathecal (IT), methotrexate ,cytarabine and dexamethasone | Sun Yat-sen University | Lymphoma, Lymphoblastic | 03/25 | 03/25 | | |
NCT03641456: VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma |
|
|
| Recruiting | 2 | 50 | RoW | bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone, Dexamethasone Acetate | Sun Yat-sen University | Myeloma, Newly Diagnosed, High Risk | 12/25 | 12/25 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT05824169: Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients |
|
|
| Recruiting | 1/2 | 18 | RoW | GC101 | GeneCradle Inc | Spinal Muscular Atrophy | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
NCT06525272: A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy |
|
|
| Not yet recruiting | 1 | 72 | RoW | Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Recombinant Human Chymotrypsin(OsrhCT), Placebo for Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Placebo for Recombinant Human Chymotrypsin(OsrhCT) | Healthgen Biotechnology Corp. | Pleurisy | 07/25 | 12/25 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
NCT04554511: Prognostic Nomogram of Extranodal NK/T-cell Lymphoma |
|
|
| Recruiting | N/A | 1000 | RoW | | Sun Yat-sen University | Extranodal NK/T-cell Lymphoma | 01/24 | 01/24 | | |
NCT03059043: Safety and Efficacy Study of A Viscoelastic-free Method for Implantable Collamer Lens (ICL) Implantation |
|
|
| Recruiting | N/A | 60 | RoW | viscoelastic-free implantation system, standard viscoelastic-assisted Implantation system | Wenzhou Medical University | Myopia | 06/26 | 06/26 | | |
| Santos, Maria CecÃlia |
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 4 | 350 | Europe, Japan, US, RoW | Belimumab (GSK1550188), BEL (BENLYSTA) | GlaxoSmithKline | Systemic Lupus Erythematosus | 04/27 | 05/29 | | |
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) |
|
|
| Recruiting | 3 | 58 | Europe, Japan, RoW | Baricitinib, LY3009104, Tocilizumab | Eli Lilly and Company | Systemic Juvenile Idiopathic Arthritis | 04/26 | 05/26 | | |
| Recruiting | 3 | 190 | Europe, Japan, RoW | Baricitinib, LY3009104 | Eli Lilly and Company | Juvenile Idiopathic Arthritis | 07/31 | 07/31 | | |
| Recruiting | N/A | 80 | Europe | Sperm capacitation through the ZyMōt®Sperm Separation Device®, Swim-up, Sperm capacitation throught swim-up technique | Instituto Valenciano de Infertilidad, IVI VALENCIA, IVI Madrid | Infertility, Male, Sperm Count, Low | 07/25 | 12/26 | | |
NCT05310838: Optimizing Engagement in Services for First-Episode Psychosis |
|
|
| Recruiting | N/A | 58 | US | Behavioral Activation for First Episode Psychosis, Treatment As Usual | California State University, San Bernardino, University of Southern California, Olive View-UCLA Education & Research Institute, National Institute of Mental Health (NIMH) | Engagement, Patient, First Episode Psychosis | 08/25 | 02/26 | | |
| Yu, Haiguo |
NCT04908865: Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE) |
|
|
| Active, not recruiting | 4 | 67 | RoW | Belimumab, Standard therapy | GlaxoSmithKline | Systemic Lupus Erythematosus | 05/24 | 09/24 | | |
| Recruiting | 3 | 190 | Europe, Japan, RoW | Baricitinib, LY3009104 | Eli Lilly and Company | Juvenile Idiopathic Arthritis | 07/31 | 07/31 | | |
NCT06417502: Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry |
|
|
| Recruiting | N/A | 20000 | RoW | | Peking Union Medical College Hospital, Children's Hospital of Chongqing Medical University, Central South University, Beijing Children's Hospital, Shenzhen Children's Hospital, Children's Hospital of Nanjing Medical University, The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI), Zhejiang University, Third Hospital of Peking University | Autoimmune Diseases, Autoinflammatory Diseases | 11/24 | 12/31 | | |
NCT05925452: To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis. |
|
|
| Recruiting | N/A | 221 | RoW | GenaKumab | Changchun GeneScience Pharmaceutical Co., Ltd. | Active Systemic Juvenile Idiopathic Arthritis | 03/28 | 06/28 | | |
| Tang, Xuemei |
NCT04908865: Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE) |
|
|
| Active, not recruiting | 4 | 67 | RoW | Belimumab, Standard therapy | GlaxoSmithKline | Systemic Lupus Erythematosus | 05/24 | 09/24 | | |
NCT06417502: Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry |
|
|
| Recruiting | N/A | 20000 | RoW | | Peking Union Medical College Hospital, Children's Hospital of Chongqing Medical University, Central South University, Beijing Children's Hospital, Shenzhen Children's Hospital, Children's Hospital of Nanjing Medical University, The University of Hong Kong Shenzhen Institute of Research and Innovation (HKU-SIRI), Zhejiang University, Third Hospital of Peking University | Autoimmune Diseases, Autoinflammatory Diseases | 11/24 | 12/31 | | |
NCT05925452: To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis. |
|
|
| Recruiting | N/A | 221 | RoW | GenaKumab | Changchun GeneScience Pharmaceutical Co., Ltd. | Active Systemic Juvenile Idiopathic Arthritis | 03/28 | 06/28 | | |
| Zhao, Yi |
| Not yet recruiting | 4 | 314 | RoW | Eldecalcitol capsules, Edirol, Alfacalcidol tablets, Calcium carbonate tablets | Chinese SLE Treatment And Research Group, Beijing Life oasis public service center | Rheumatoid Arthritis, Osteoporosis, Osteopenia | 12/25 | 03/26 | | |
| Recruiting | 4 | 100 | RoW | Adalimumab Injection, An-jian-ning, Tofacitinib 5 MG, An-shu-zheng | Chinese SLE Treatment And Research Group | Takayasu Arteritis | 01/26 | 01/26 | | |
NCT05793892: Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults |
|
|
| Completed | 3 | 286 | RoW | Lidocaine tetracaine cream, test drug:CU-30101, control drug:Pliaglis | Cutia Therapeutics（Wuxi）Co.,Ltd | Analgesia | 08/23 | 10/23 | | |
NCT06145893: A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease |
|
|
| Recruiting | 3 | 162 | RoW | Hemay005, Mufemilast, Phosphodiesterase 4 (PDE4) inhibitors, Placebo | Ganzhou Hemay Pharmaceutical Co., Ltd | Behçet's Disease | 11/24 | 03/25 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06280716: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 430 | RoW | Placebo, Lebrikizumab, LY3650150, Topical Corticosteroid | Eli Lilly and Company | Atopic Dermatitis | 12/25 | 11/26 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 491 | Europe, Canada, Japan, US, RoW | Peresolimab, Placebo | Eli Lilly and Company | Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases | 11/23 | 01/25 | | |
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 64 | RoW | GT101 injection, Gemcitabine injection | Grit Biotechnology | Adult | 01/27 | 01/27 | | |
TARIC-1, NCT06178419: Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis |
|
|
| Recruiting | N/A | 44 | RoW | RIC, sham-RIC | Xuanwu Hospital, Beijing | Cerebral Ischemia, Takayasu Arteritis | 07/25 | 07/25 | | |
NCT06023147: A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | N/A | 298 | RoW | E-TACE | Xuhua Duan | Hepatocellular Carcinoma | 09/24 | 09/25 | | |
NCT04989153: Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer |
|
|
| Recruiting | N/A | 5000 | RoW | pepsinogen | Second Affiliated Hospital, School of Medicine, Zhejiang University, Jilin City People's Hospital, No. 924 Hospital of the People's Liberation Army of China, Kunshan Hospital of Traditional Chinese Medicine, Chinese PLA General Hospital, Sichuan Provincial People's Hospital, Affiliated Hospital of Southwest Medical University, Zhongshan Hospital Xiamen University, Jingzhou Hospital of Traditional Chinese Medicine, Changhai Hospital | Gastric Cancer, Precancerous Lesion, Helicobacter Pylori Infection | 12/22 | 12/23 | | |
| Schuller, Marcel |
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) |
|
|
| Recruiting | 3 | 58 | Europe, Japan, RoW | Baricitinib, LY3009104, Tocilizumab | Eli Lilly and Company | Systemic Juvenile Idiopathic Arthritis | 04/26 | 05/26 | | |
| Recruiting | 3 | 190 | Europe, Japan, RoW | Baricitinib, LY3009104 | Eli Lilly and Company | Juvenile Idiopathic Arthritis | 07/31 | 07/31 | | |
